跳至主要内容

Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China

 On February 15, the Class 1 new drug Carenoprazan Hydrochloride Tablets, for the treatment of duodenal ulcer and reflux esophagitis, independently developed by Jiangsu Carephar Pharmaceutical (Carephar) was officially approved for sales in market.



Shanghai Medicilon Inc. (Medicilon), as a partner of Carephar, with its solid research and development capabilities, has provided Carenoprazan’s research and development from compound design to preclinical candidate compounds, as well as most of the in vitro H+K+-ATPase testing and other services and the Carenoprazan has been successfully approved.

Medicilon Drug Discovery Services
Open the door to innovative medicine with science and expertise

Drug discovery is the first stage of drug development and a key element that directly affects the success of new drug development.  As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon can provide one-stop service for drug discovery after 19 years of intensive innovation.

Medicilon can undertake different kind of chemistry services such as custom synthesis, compound library construction, SAR compound synthesis and screening, and compound structure and biological activity optimization.  In terms of biology services, Medicilon could provide reparation of hybridoma antibody/genetic engineering antibody, protein expression and purification, X-ray crystal structure analysis/cryo-electron microscopy protein structure analysis, small molecule/antibody drug conjugate/antibody-dependent cell-mediated cytotoxicity detection, organoid drug screening, screening of small molecule inhibitors/agonists targeting enzymes/receptors, protein-protein/protein-small molecule affinity determination, virtual screening and computer simulation-assisted drug design, gene editing and stable cell line construction, CAR-T/CAR-NK construction and target cell killing experiments, M9 selenium medium preparation, as well as research services on the molecular mechanism of drugs.

标签：

评论

发表评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...
发表评论
阅读全文

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...
发表评论
阅读全文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文